52
45. Mahler DA, Wire P, Horstman D, et al. Effectiveness of fluticasone propionate
and salmeterol combination delivered via the diskus device in the treatment of
chronic obstructive pulmonary disease. Am J Respir Crit Care Med
2002;1
66(8):1084
-
1091.
46. Mammarella R. Moradia irregular e condições de vida na região metropolitana de
Porto Alegre: uma visão preliminar.
Indic Econ FEE 2004;32:33
-64.
47. Mannino DM, Brown C, Giovino GA. Obstructive lung disease deaths in the
United States from 1979 through 1993: an analysis using multiple-cause mortality
data. Am J Respir Crit Care Med 1997;156:814
818.
48. Medical Research Council Working Party. Long term domiciliary oxygen therapy
in chronic hypoxic cor pulmonale complicating chronic bronchitis and
emphysema. Lancet 1981;1:681-
686.
49. Menezes AMB, Perez-Padilla R, Jardim JB, et al. Chronic obstructive pulmonary
disease in five Latin American cities (the PLATINO study): a prevalence study.
Lancet 2005;366:1875
-
1881.
50. Michaud CM,D, Murray CJ, Bloom DB. Burden of disease implications for future
research. JAMA 2001;285:535
-
539.
51. Ministério da Saúde, Instituto Nacional do Câncer, Coordenação de Prevenção e
Vigilância. Prevalência de tabagismo no Brasil
Dados dos inquéritos
epidemiológicos em capitais brasileiras. 2004. Disponível em
http://portal.saude.gov.br/portal/arquivos/pdf/tabaco_inquerito_nacional_070504.
pdf. Acessado em 07de novembro de 2005.
52. Mokdad AH, Marks JS, Stroup DF, et al. Actual causes of death in the United
States, 2000. JAMA 2004;291:1238
-
124
5.
53. National Institutes of Health, National Heart, Lung, and Blood Institute. Clinical
Guidelines on the Identification, Evaluation, and Treatment of Overweight and
Obesity in Adults. June 1998. Disponível em http://www.nhlbi.nih.gov/
guidelines/obesity/ob
_gdlns.pdf. Acessado em 7 de setembro de 2005.
54. Nishimura K, Izumi T, Tsukino M, et al. Dyspnea is a better predictor of 5-
year
survival than airway obstruction in patients with COPD. Chest 2002;121(5):1434-
1440.
55. Nocturnal Oxygen Therapy Trial Group. Continuous or nocturnal oxygen therapy
in hypoxemic chronic obstructive lung disease: a clinical trial. Ann Intern Med
1980;93:391
-
398.
56.
Oswald
-Mammosser M, Weitzenblum E, Quoix E, et al. Prognostic factors in
COPD patients receiving long-term oxygen therapy. Importance of pulmonary
artery pressure. Chest 1995;107:1193
-
1198.
57. Pauwels RA, Lofdahl CG, Laitinen LA, et al.
Long
-term treatment with inhaled
budesonide in persons with mild chronic obstructive pulmonary disease who
continue smoking. European Respiratory Society Study on Chronic Obstructive
Pulmonary Disease. N Engl J Med 1999;340:1948
-
1953.